These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27588383)

  • 1. Statistical Considerations in the Development of Clinical Predictive Scores: Comment on the Article by Domsic et al.
    Collignon O; Veselý R
    Arthritis Rheumatol; 2017 Jan; 69(1):241-242. PubMed ID: 27588383
    [No Abstract]   [Full Text] [Related]  

  • 2. Does subclinical atherosclerosis really exist in systemic sclerosis? Comment on the article by Turiel et al.
    Vacca A; Montisci R; Garau P; Mathieu A
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2062-3. PubMed ID: 24022883
    [No Abstract]   [Full Text] [Related]  

  • 3. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
    Sultan N; Pope JE; Clements PJ;
    Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [On the morphology of the autonomic nervous system of the human skin with studies on neuropathological changes in various skin diseases. Neurohistological studies on lichen sclerosus et atrophicus, superficial, small-spotted scleroderma and diffuse scleroderma with comparative pathogenetic considerations. Part IV].
    THIES W
    Z Haut Geschlechtskr; 1960 Jan; 28():37-59. PubMed ID: 13837846
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma: comments on the article by Danielides et al.
    Park SJ; Shin JI
    Scand J Rheumatol; 2012 May; 41(3):248. PubMed ID: 22548259
    [No Abstract]   [Full Text] [Related]  

  • 6. [Histogenetic considerations on a case of extenso-progressive scleroderma].
    ROSSI L; CIOCIA D
    Osp Maggiore; 1951 Feb; 39(2):80-7. PubMed ID: 14827579
    [No Abstract]   [Full Text] [Related]  

  • 7. [Diffuse scleroderma in a 5-year-old boy. Considerations on a case].
    FRANCK RR
    Hospital (Rio J); 1961 Sep; 60():327-32. PubMed ID: 13894524
    [No Abstract]   [Full Text] [Related]  

  • 8. Errors in Table 3 of the Article by Domsic et al (Arthritis Rheumatol, April 2016).
    Arthritis Rheumatol; 2016 Nov; 68(11):2751. PubMed ID: 27785909
    [No Abstract]   [Full Text] [Related]  

  • 9. Toward personalized medicine in scleroderma: classification of scleroderma patients into stable "inflammatory" and "fibrotic" subgroups.
    Leask A
    J Invest Dermatol; 2012 May; 132(5):1329-31. PubMed ID: 22499038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Herrick AL; Lunt M; Silman AJ; Denton CP
    Rheumatology (Oxford); 2010 Aug; 49(8):1607-8; author reply 1608. PubMed ID: 20427293
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathogenesis of diffuse scleroderma].
    ORMEA F
    Hautarzt; 1952 Jul; 3(7):301-4. PubMed ID: 12980477
    [No Abstract]   [Full Text] [Related]  

  • 12. Diffuse scleroderma.
    SACKS DR; INMON TW; O'NEILL JR
    Tex State J Med; 1950 Jan; 46(1):37-43, illust. PubMed ID: 15399979
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical study of visceral lesions and endocrine disturbances in eight cases with diffuse scleroderma.
    ROBLES GIL J
    Ann Rheum Dis; 1948 Dec; 7(4):250. PubMed ID: 18100851
    [No Abstract]   [Full Text] [Related]  

  • 14. [Diffuse generalized scleroderma].
    KINTZEN W
    Arch Dermatol Syph; 1952; 194(3):239-58. PubMed ID: 14953205
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of diffuse progressive scleroderma.
    EVANS JA; RUBITSKY HJ; PERRY AW
    J Am Med Assoc; 1953 Mar; 151(11):891-9. PubMed ID: 13022338
    [No Abstract]   [Full Text] [Related]  

  • 16. [On the relation between circumscribed and diffuse scleroderma].
    JABLONSKA S; BUBNOW B; SZCZEPANSKI A
    Pol Tyg Lek; 1961 Nov; 16():1733-9. PubMed ID: 14450538
    [No Abstract]   [Full Text] [Related]  

  • 17. [Extracutaneous manifestations of diffuse scleroderma. I. Report on needle biopsy of the liver in scleroderma].
    ORMEA F; APRA A
    Minerva Dermatol; 1955 Dec; 30(12):395-7. PubMed ID: 13296932
    [No Abstract]   [Full Text] [Related]  

  • 18. [Kidneys in diffuse systemic sclerosis].
    Dębowska M; Staszków M
    Wiad Lek; 2016; 69(5):717-720. PubMed ID: 28033593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histologic investigations of diffuse (progressive) scleroderma, circumscript scleroderma and sclerodermoid modifications in acrodermatitis chronica atrophicans].
    REICH
    Arch Dermatol Syph; 1950; 191():505-15. PubMed ID: 14790667
    [No Abstract]   [Full Text] [Related]  

  • 20. Diffuse scleroderma.
    LANCELEY JL
    J Trop Med Hyg; 1962 Feb; 65():34-7. PubMed ID: 14461917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.